Shobhana A. Raju

Sedam Road
Gulbarga, KA 585105, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Role of [ 18 F]fluorodeoxyglucose positron emission tomography-computed tomography metabolic radiomics in predicting response to chemotherapy in patients with non-small cell lung cancer.

Role of [ 18 F]fluorodeoxyglucose positron emission tomography-computed tomography metabolic radiomics in predicting response to chemotherapy in patients with non-small cell lung cancer.

Journal: Nuclear medicine communications

Published: February 19, 2026

Dual-Tracer PET/CT in Erysipelas-like Cutaneous Metastases From Salivary Duct Adenocarcinoma: FAPI Illuminates What FDG Missed.

Dual-Tracer PET/CT in Erysipelas-like Cutaneous Metastases From Salivary Duct Adenocarcinoma: FAPI Illuminates What FDG Missed.

Journal: Clinical nuclear medicine

Published: August 04, 2025

Complete Response to 177 Lu-DOTATATE PRRT in a 9-Year-Old Child With Metastatic Carotid Body Paraganglioma.

Complete Response to 177 Lu-DOTATATE PRRT in a 9-Year-Old Child With Metastatic Carotid Body Paraganglioma.

Journal: Clinical nuclear medicine

Published: November 17, 2023

Impact of forced diuresis at two different time points on pelvic imaging in prostatic carcinoma with 68 Ga-PSMA PET/CT.

Impact of forced diuresis at two different time points on pelvic imaging in prostatic carcinoma with 68 Ga-PSMA PET/CT.

Journal: Nuclear medicine communications

Published: October 06, 2023

Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study.

Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study.

Journal: European journal of nuclear medicine and molecular imaging

Published: May 23, 2023

Head-to-Head Comparison of [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DOTANOC Positron Emission Tomography/Computed Tomography Imaging for the Follow-Up Surveillance of Patients with Medullary Thyroid Cancer.

Head-to-Head Comparison of [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DOTANOC Positron Emission Tomography/Computed Tomography Imaging for the Follow-Up Surveillance of Patients with Medullary Thyroid Cancer.

Journal: Thyroid : official journal of the American Thyroid Association

Published: May 12, 2023

[177Lu]Lu-DOTAGA.Glu.(FAPi)2 Radionuclide Therapy: a New Treatment Option for Patients with Glioblastoma Multiforme.

[177Lu]Lu-DOTAGA.Glu.(FAPi)2 Radionuclide Therapy: a New Treatment Option for Patients with Glioblastoma Multiforme.

Journal: Nuclear medicine and molecular imaging

Published: April 07, 2023

Head-to-Head Comparison between [68Ga]Ga-DOTA.SA.FAPi and [18F]F-FDG PET/CT Imaging in Patients with Breast Cancer.

Head-to-Head Comparison between [68Ga]Ga-DOTA.SA.FAPi and [18F]F-FDG PET/CT Imaging in Patients with Breast Cancer.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: February 20, 2023

Discordant Molecular Imaging Findings with 2-[18F]FDG and [68Ga]Ga-PSMA PET/CT in a Patient with Both Bladder and Prostate Cancer.

Discordant Molecular Imaging Findings with 2-[18F]FDG and [68Ga]Ga-PSMA PET/CT in a Patient with Both Bladder and Prostate Cancer.

Journal: Nuclear medicine and molecular imaging

Published: December 29, 2022

Fibroblast Activation Protein Inhibitor Theranostics.

Fibroblast Activation Protein Inhibitor Theranostics.

Journal: PET clinics

Published: June 18, 2022

An Appraisal and Update of Fluorodeoxyglucose and Non-Fluorodeoxyglucose-PET Tracers in Thyroid and Non-Thyroid Endocrine Neoplasms.

An Appraisal and Update of Fluorodeoxyglucose and Non-Fluorodeoxyglucose-PET Tracers in Thyroid and Non-Thyroid Endocrine Neoplasms.

Journal: PET clinics

Published: June 18, 2022

Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?

Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?

Journal: Nuclear medicine communications

Published: August 16, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026